Targeting the HER3-phosphatidyl inositol-3 kinase pathway in breast cancers (SABCS 2012) - Dec 10, 2012 - "...Luminal breast tumor xenografts treated with U3-1287, a humanized monoclonal anti-ErbB3 antibody, or EZN-3920, an anti-sense oligonucleotide against ErbB3, decreased tumor growth and phosphatidyl inositol-3 kinase (PI3K)/mTOR signaling in vivo..."
Preclinical • Breast Cancer • Oncology
|
|
35th Annual San Antonio Breast Cancer Symposium (SABCS), Dec 4-8, 2012, SA, Texas.
|
|
P5-19-01
"…Luminal breast tumor xenografts treated with U3-1287, a humanized monoclonal anti-ErbB3 antibody, or EZN-3920, an anti-sense oligonucleotide against ErbB3, decreased tumor growth and phosphatidyl inositol-3 kinase (PI3K)/mTOR signaling in vivo. Interestingly, luminal breast tumor xenografts responded to the ER inhibitor fulvestrant with increased HER3 expression..."
|